跳至主要内容
临床试验/IRCT20161207031288N13
IRCT20161207031288N13招募中2 期

Evaluation of safety and efficacy of Nanostructured lipid carrier( NLC) nanoparticles containing hydroquinone, tretinoin, and fluocinolone compared with conventional formulation in the treatment of melasma

Tehran University of Medical Sciences0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • 18 - 50 years old men and women
  • Case of approximately symmetrical moderate to severe melasma (melasma global severity score(MGSC)>2)
  • No topical and systemic treatment for melasma during the last 4 weeks
  • Appropriate general health condition
  • No change in life style during the study
  • Signing the consent form of the candidate to participate in the study and the desire to attend regular follow-up courses

排除标准

  • Pregnant people or those who plan to become pregnant during the study
  • People with known allergies to any of the components of the cream
  • History of using each of the mentioned compounds topically in the last 21 days: Corticosteroids, retinoid compounds, chemical peels, alpha hydroxy acid and beta hydroxy acid compounds
  • History of systemic use of each of the mentioned compounds in the last 28 days: corticosteroids, tretinoin compounds, interferon types
  • Patients with rosacea, skin atrophy, acne and eczema
  • History of use of drugs that increase photosensitivity in the last 3 months
  • People who have had laser skin peeling or microdermabrasion in the last 3 months
  • If the doctor of the study determines that the volunteer is not appropriate for this study by some reaons

研究者

相似试验

Evaluation of NLC nanoparticles containing... | 临床试验